Lung cancer diagnostics developer bioAffinity Technologies files for a $15 million IPO - Renaissance Capital

bioAffinity Technologies, which is developing a noninvasive test for early detection of lung cancer, filed on Monday with the SEC to raise up to $15 million in an initial public offering.

IPO Pro - "The Ultimate Resource for IPOs" Don't risk buying another IPO without IPO Pro.Get your FREE TRIAL now. Start My 1-Week Trial

full article...